MAPT and Alzheimer disease: Furthermore, a phase-2 study of humanized monoclonal antibody RO7105705, which binds to the C terminal region of tau, reported that the treatment group showed rapid and robust amyloid plaque clearances and changes in relevant downstream biomarkers among patients with prodromal or mild to moderate AD.